IGF-1 and prostate cancer

Novartis Foundation Symposium

Volumn 262, Issue , 2004, Pages 193-204

  Roberts Jr , Charles T ^a   Holly, ^a  

^a NRC5 ^*

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

ANIMAL; HUMAN; MALE; METABOLISM; PHYSIOLOGY; PROSTATE TUMOR; REVIEW;

ANIMALS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; PROSTATIC NEOPLASMS; RECEPTOR, IGF TYPE 1;

EID: 13244294871     PISSN: None     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Article

References (35)

1. Baffa R, Reiss K, El-Gabry EA et al 2000 Low serum insulin-like growth factor 1 (IGF-1): a significant association with prostate cancer. Tech Urol 6:236-239
2. Boudon C, Rodier G, Lechevallier E, Mottet N, Barenton B, Sultan C 1996 Secretion of insulin-like growth factors and their binding proteins by human normal and hyperplastic prostatic cells in primary culture. J Clin Endocrinol Metab 81:612-617
3. Burfeind P, Chernicky CL, Rininsland F, Ilan J, Ilan J 1996 Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo. Proc Natl Acad Sci USA 93:7263-7268
4. Chan JM, Stampfer MJ, Ma J et al 2002 Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 94:1099-1106
5. Chott A, Sun Z, Morganstern D et al 1999 Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of type 1 insulin-like growth factor receptor. Am J Pathol 155:1271-1279
6. Cohen P 1998 Serum insulin-like growth factor I levels and prostate cancer risk -interpreting the evidence. J Natl Cancer Inst 90:876-876
7. Cohen P, Peehl DM, Rosenfeld RG 1994 The IGF axis in the prostate. Horm Metab Res 26: 81-84
8. Cutting CW, Hunt C, Nisbet JA, Bland JM, Dalgleish AG, Kirby RS 1999 Serum insulin-like growth factor-1 is not a useful marker of prostate cancer. BJU Int 83:996-999
9. Damon SE, Plymate SR, Carroll JM et al 2001 Transcriptional regulation of insulin-like growth factor-I receptor gene expression in prostate cancer cells. Endocrinology 142:21-27
10. DiGiovanni J, Kiguchi K, Frijhoff A et al 2000 Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice. Proc Natl Acad Sci USA 97:3455-3460
11. Djavan G, Bursa B, Seitz C et al 1999 Insulin-like growth factor 1 (IGF-1), IGF-1 density, and IGF-1/PSA ratio for prostate cancer detection. Urology 54:603-606
12. Finne P, Auvinen A, Koistinen H et al 2000 Insulin-like growth factor I is not a useful marker of prostate cancer in men with elevated levels of prostate-specific antigen. J Clin Endocrinol Metab 85:2744-2747
13. Happerfield LC, Miles DW, Barnes DM, Thomsen LL, Smith P, Hanby AM 1997 The localization of the insulin-like growth factor receptor 1 (IGFR-1) in benign and malignant breast tissue. J Pathol 183:412-417
14. Harman SM, Metter EJ, Blackman MR, Landis PK, Carter HB 2000 Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictor of clinical prostate cancer J Clin Endocrinol Metab 85:4258-4265
15. Hellawell GO, Turner GD, Davies DR, Poulsom R, Brewster SF, Macaulay VM 2002 Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res 62:2942-2950
16. Huynh H, Seyam RM, Brock GB 1998 Reduction of ventral prostate weight by finasteride is associated with suppression of insulin-like growth factor I (IGF-I) and IGF-I receptor genes and with an increase in IGF binding protein 3. Cancer Res 58:215-218
17. Kaplan PJ, Mohan S, Cohen P, Foster BA, Greenberg NM 1999 The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Cancer Res 59:2203-2209
18. Kurek R, Tunn UW, Eckart O, Aumuller G, Wong J, Renneberg H 2000 The significance of serum levels of insulin-like growth factor-1 in patients with prostate cancer. BJU Int 85:125-129
19. Latif Z, McMillan DC, Wallace AM et al 2002 The relationship of circulating insulin-like growth factor 1, its binding protein-3, prostate-specific antigen and C-reactive protein with disease stage in prostate cancer. BJU Int 89:396-399
20. Mantzoros CS, Tzonou A, Signorello LB, Stampfer M, Trichopoulos D, Adami HO 1997 Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer 76:1115-1118
21. Ng YK, Teng SP, Bales W, Rodeck U, Veltri RW 1996 Increased expression of Wilms' tumor protein (WT1) in prostate cancer. In: 87th Annual Meeting of the American Association of Cancer Research, Washington DC, p 599
22. Nickerson T, Chang F, Lorimer D, Smeekens SP, Sawyers C, Pollak M 2001 In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res 61:6276-6280
23. Peehl DM, Cohen P, Rosenfeld RG 1994 The insulin-like growth factor system in the prostate. World J Urol 13:306-311
24. Plymate S, Bae VL, Maddison L, Quinn LS, Ware JL 1997 Reexpression of the type I insulin-like growth factor receptor inhibits the malignant phenotype of simian virus 40 T antigen immortalized human prostate epithelial cells. Endocrinology 138:1728-1735
25. Plymate SR, Tennant MK, Culp SH et al 2004 Androgen receptor (AR) expression in AR-negative prostate cancer cells results in differential effects of DHT and IGF-1 on proliferation and AR activity between localized and metastatic tumors. Prostate, in press
26. Ruan W, Powell-Braxton L, Kopchick JJ, Kleinberg DL 1999 Evidence that insulin-like growth factor I and growth hormone are required for prostate gland development. Endocrinology 140:1984-1989
27. Rubini M, Hongo A, D'Ambrosio C, Baserga R 1997 The IGF-I receptor in mitogenesis and transformation of mouse embryo cells: role of receptor number. Exp Cell Res 230:284-292
28. Shaneyfelt T, Husein R, Bubley G, Mantzoros CS 2000 Hormonal predictors of prostate cancer: a meta-analysis. J Clin Oncol 18:847-853
29. Shi R, Berkel HJ, Yu H 2001 Insulin-like growth factor-I and prostate cancer: a meta-analysis. Br J Cancer 85:991-996
30. Sperandio S, de Belle I, Bredesen DE 2000 An alternative, nonapoptotic form of programmed cell death. Proc Natl Acad Sci USA 97:14376-14381
31. Stattin P, Bylund A, Rinaldi S et al 2000 Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst 92:1910-1917
32. Tennant MK, Thrasher JB, Twomey PA, Drivdahl RH, Birnbaum RS, Plymate S 1996 Protein and mRNA for the type 1 insulin-like growth factor (IGF) receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium. J Clin Endocrinol Metab 81:3774-3782
33. Torring N, Vinter-Jensen L, Pederson SB, Sorensen FB, Flyvbjerg A, Nexo E 1997 Systemic Administration of insulin-like growth factor I (IGF-I) causes growth of the rat prostate. J Urol 158:222-227
34. Werner H, Rauscher FJ 3rd, Sukhatme VP, Drummond IA, Roberts CT Jr, LeRoith D 1994 Transcriptional repression of the insulin-like growth factor I receptor (IGF-I-R) gene by the tumor suppressor WT1 involves binding to sequences both upstream and downstream of the IGF-IR gene transcription start site J Biol Chem 269:12577-12582
35. Wolk A, Mantzoros CS, Andersson SO et al 1998 Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst 90:911-915